Hyperfine’s Swoop system, the first U.S. Food and Drug Administration (FDA)-cleared AI-powered portable MRI system for the brain, showed strong diagnostic agreement with conventional MRI scans and was preferred by patients, according to new study results. Because Swoop can be used in neurology clinics, it may help make…
MRI
Multiple sclerosis (MS) may follow two distinct biological paths that differ in how early and how quickly nerve damage develops, according to a new study. Using artificial intelligence (AI) to analyze brain MRI scans together with a blood test linked to nerve damage, researchers identified one MS pattern marked…
Children with multiple sclerosis (MS) who have more paramagnetic rim lesions (PRLs) — areas of chronic active inflammation seen on MRI scans — tend to lose more brain volume over time, a new study found. These lesions were common in pediatric MS, a rare form of the disease…
Gadoquatrane, a contrast agent Bayer is developing for MRI scans, showed similar safety and pharmacokinetic (PK) profiles — meaning how a drug moves into, through, and out of the body — in both children and adults. That’s according to data from the Phase 3 QUANTI Pediatric study (NCT05915026),…
More than 3 million doses of Vueway (gadopiclenol), a lower-dose gadolinium contrast MRI agent used to diagnose and monitor conditions such as multiple sclerosis (MS), have been administered at more than 900 customer sites, maker Bracco Diagnostics said. Approved by the U.S. Food and Drug Administration for use in children…
A new technique is letting scientists peer into the brain’s wiring with greater detail by simply using a microscope and an LED light, an accessible and cost-effective method that may be useful for studying brain damage in neurological diseases such as multiple sclerosis (MS). The method, called Computational Scattered…
A new wearable brain-mapping tool could dramatically change how doctors monitor people with multiple sclerosis (MS), making it easier to track disease progression and guide personalized care. Researchers showed the system, OPM-MEG, reliably detects abnormalities in the brain’s electrical activity in MS patients. The portable technology is a major…
Researchers have developed a highly sensitive imaging technique that can detect damage to myelin, the fatty wrapping around nerve fibers that is damaged in multiple sclerosis (MS), in large areas of the brain, according to a study. The tool may help assess the extent of myelin damage in…
Doctors will be able to diagnose multiple sclerosis (MS) faster and with greater accuracy — allowing patients to access treatment and support earlier — following an update to the McDonald criteria, the official guidelines used to diagnose the condition. The revision reflects advances in understanding the biology of…
Paramagnetic rim lesions (PRLs), which represent areas of damage in the brain and spinal cord with chronic active inflammation, are highly indicative of multiple sclerosis (MS) in people being evaluated for the disease, a new study reports. The findings support using this imaging biomarker as a useful tool for…
The International Progressive MS Alliance has introduced the MS Clinical and Imaging Data Resource, or CIDR, to accelerate the search for effective treatments for progressive forms of multiple sclerosis (MS) where options are limited. The resource was built in partnership with McGill University in Canada, as well as…
A new positron emission tomography (PET) tracer may help determine the extent of nerve fiber loss in multiple sclerosis (MS) lesions, something that can’t be identified with conventional MRI imaging, according to a new study. Researchers think the new imaging tech could help track the efficacy of experimental therapies…
A type of imaging finding called iron rim lesions are associated with more severe disability and a greater extent of brain damage in people with multiple sclerosis (MS), a new analysis suggests. This specific imaging finding may help guide discussions about individualized treatments for MS, the study’s researchers said.
A new imaging technology may help detect early signs of brain damage in people with multiple sclerosis (MS) that aren’t visible on conventional MRI scans, a recent study shows. The technology detects specific metabolic alterations in the brain by tracking certain metabolites and neurotransmitters — molecules that nerve…
The first person with multiple sclerosis (MS) has been successfully imaged in a clinical trial evaluating a new positron emission tomography (PET) tracer designed to detect changes in myelin loss, or demyelination. The Phase 1 study (NCT04699747), a joint effort between Quantum Biopharma and Massachusetts…
In people with benign relapsing-remitting multiple sclerosis (RRMS) who have minimal disease activity, there is a loss of overall brain tissue but specific parts of the brain may grow to help compensate for the damage, a new study indicates. The study, “AI-driven MRI analysis reveals brain…
A particular finding on an MRI scan, called the central vein sign (CVS), is sufficient to support a multiple sclerosis (MS) diagnosis without the need for an invasive lumbar puncture, a new U.K. study suggests. The presence of six lesions with a CVS, where a vein is found…
People with multiple sclerosis (MS) who experience progression independent of relapse activity (PIRA) tend to have greater damage to major white matter tracts, or bundles of nerve fibers that connect different regions of the brain, a new study reports. The findings offer some insights into the biological processes that…
Certain lesions in the spinal cords of people with multiple sclerosis (MS) show damage to nerve fibers despite having normal myelin, according to a study done on postmortem samples using powerful MRI scans paired with detailed tissue analyses. The identification of these lesions “provides a novel opportunity to detect…
Well, it’s that time of year again, and I’m not referring to allergy season or baseball. It’s time for my MRI to evaluate my multiple sclerosis (MS). For the last three years, I was getting an MRI every 18 months. But at my last visit I saw a…
Before I received my relapsing-remitting multiple sclerosis (MS) diagnosis in 2016, I underwent a standard MRI exam, with and without contrast, that scanned my brain, thorax, and cervical spine. I’d never had an MRI before this one. I was vaguely familiar with what the machine looked like, but it’s…
Sanofi‘s oral BTK inhibitor tolebrutinib significantly delayed the onset of six-month confirmed disability progression compared with a placebo, by 31%, in people with nonrelapsing secondary progressive multiple sclerosis (SPMS). That’s according to recently published data from the HERCULES Phase 3 trial (NCT04411641), where the experimental therapy…
A new artificial intelligence (AI) tool called MindGlide can accurately calculate, from a single MRI scan, multiple aspects of brain damage related to multiple sclerosis (MS) — even when employed with routine scans that are not typically used to monitor such damage. The development and validation of the tool…
Evidence of neurological damage over time — known as dissemination in time, or DIT — may not be necessary to reach a diagnosis of multiple sclerosis (MS) for all patients, according to a report by U.K. researchers. Traditionally, an MS diagnosis would typically require both DIT and DIS,…
Proposed revisions to the McDonald criteria, a set of diagnostic guidelines for multiple sclerosis (MS), may help diagnose people who could have been missed under earlier versions, according to a recent analysis. That includes people with radiological-only onset, when there are signs of disease on MRI scans but…
A Phase 2 clinical trial is currently recruiting adults with relapsing types of multiple sclerosis (MS) to investigate Zenas Biopharma’s experimental therapy obexelimab as a weekly subcutaneous, or under-the-skin, injection, the company has announced in a press release. The study, called MoonStone (NCT06564311), is open to…
Enigma Biomedical has entered into an agreement with Neuraly to use its PET imaging tracer PMI04 to visualize microglia activity in people with neurodegenerative diseases such as multiple sclerosis (MS). Microglia are resident immune cells in the brain that are believed to play a role in driving…
Gadoquatrane, a contrast agent Bayer is developing for use in MRI scans, is able to detect regions of damage and other disease-related features while using 60% less gadolinium — a chemical element used to enhance an MRI — compared with existing gadolinium-based contrast agents. That’s according to new data…
A specific type of brain lesion called a paramagnetic rim lesion, or PRL, is associated with worse disability over time in people with multiple sclerosis (MS), but available disease-modifying therapies (DMT) can lower the chances of the appearance of these lesions, according to two studies published by scientists…
The U.S. Food and Drug Administration (FDA) has cleared an extended version of Neurophet Aqua, an MRI analysis software that uses artificial intelligence (AI) to measure disease-related changes in brain scans. Earlier clearance enabled Neurophet‘s software to analyze brain atrophy using T1-weighed MRI scans in people with neurodegenerative conditions.